



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE.

34th Edition

CLSI M100™

Performance Standards for Antimicrobial Susceptibility Testing

CLSI M100 includes updated tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing standards CLSI M02, M07, and M11.

A CLSI supplement for global application.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the *CLSI Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

www.clsi.org

standard@clsi.org

Performance Standards for Antimicrobial Susceptibility Testing

James S. Lewis II, PharmD, FIDSA
Amy J. Mathers, MD, D(ABMM)
April M. Bobenchik, PhD, D(ABMM)
Alexandra Lynn Bryson, PhD, D(ABMM)
Shelley Campeau, PhD, D(ABMM)
Sharon K. Cullen, BS, RAC
Tanis Dingle, PhD, D(ABMM), FCCM
Marcelo F. Galas, BSc
Romney M. Humphries, PhD, D(ABMM), FIDSA
Thomas J. Kirn, Jr., MD, PhD

Brandi Limbago, PhD
Virginia M. Pierce, MD, FIDSA
Sandra S. Richter, MD, D(ABMM), FIDSA
Michael Satlin, MD, MS
Audrey N. Schuetz, MD, MPH, D(ABMM)
Susan Sharp, PhD, D(ABMM), F(AAM)
Patricia J. Simmer, PhD, D(ABMM)
Pranita D. Tamma, MD, MHS
Melvin P. Weinstein, MD

Abstract

The data in the tables are valid only if the methodologies in CLSI M02,¹ M07,² and M11³ are followed. These standards contain information about disk diffusion (CLSI M02¹) and dilution (CLSI M07² and CLSI M11³) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treating their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tables presented in CLSI M100 represent the most current information for drug selection, interpretation, and quality control using the procedures standardized in CLSI M02,¹ M07,² and M11.³ Users should replace previously published tables with these new tables. Changes in the tables since the previous edition appear in boldface type.

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing*. 34th ed. CLSI supplement M100 (ISBN 978-1-68440-220-5 [Print]; ISBN 978-1-68440-221-2 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2024.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100 **F:** +1.610.688.0700 **E:** customerservice@clsi.org **W:** www.clsi.org